肺炎支原体对几种新型喹诺酮类、四环素类和红霉素的敏感性。
Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
作者信息
Kenny G E, Cartwright F D
机构信息
Department of Pathobiology, University of Washington School of Public Health and Community Medicine, Seattle 98195.
出版信息
Antimicrob Agents Chemother. 1991 Mar;35(3):587-9. doi: 10.1128/AAC.35.3.587.
Abstract
Mycoplasma pneumoniae (39 strains) was most susceptible to two quinolones, WIN 57273 and sparfloxacin, with MICs for 90% of the strains (MIC90S) of 0.125 and 0.25 micrograms/ml, respectively. It was susceptible to ofloxacin and ciprofloxacin at 2 micrograms/ml and to lomefloxacin and fleroxacin at 4 micrograms/ml. The MIC90 of erythromycin was 0.062 microgram/ml, and that of tetracycline was 1 microgram/ml.
摘要
肺炎支原体（39株）对两种喹诺酮类药物——WIN 57273和司帕沙星最为敏感，90%菌株的最低抑菌浓度（MIC90s）分别为0.125微克/毫升和0.25微克/毫升。它对氧氟沙星和环丙沙星的MIC为2微克/毫升，对洛美沙星和氟罗沙星的MIC为4微克/毫升。红霉素的MIC90为0.062微克/毫升，四环素的MIC90为1微克/毫升。
相似文献
1
Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
Antimicrob Agents Chemother. 1991 Mar;35(3):587-9. doi: 10.1128/AAC.35.3.587.
2
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
Antimicrob Agents Chemother. 1991 Jun;35(6):1181-5. doi: 10.1128/AAC.35.6.1181.
3
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Antimicrob Agents Chemother. 1992 Apr;36(4):856-9. doi: 10.1128/AAC.36.4.856.
4
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.
Antimicrob Agents Chemother. 1991 Jul;35(7):1515-6. doi: 10.1128/AAC.35.7.1515.
5
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
6
Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):433-5. doi: 10.1016/0732-8893(89)90115-6.
7
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
8
In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
Antimicrob Agents Chemother. 1994 Apr;38(4):738-41. doi: 10.1128/AAC.38.4.738.
9
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
J Antimicrob Chemother. 1997 Aug;40(2):308-9. doi: 10.1093/jac/40.2.308.
10
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388.
引用本文的文献
1
In vitro susceptibility test of Xiao'er Feire Kechuan Oral Solution to Mycoplasma pneumoniae.
Medicine (Baltimore). 2019 Jul;98(27):e16070. doi: 10.1097/MD.0000000000016070.
2
Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.
BMC Infect Dis. 2015 Apr 25;15:197. doi: 10.1186/s12879-015-0933-9.
3
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
4
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Antimicrob Agents Chemother. 2001 Sep;45(9):2604-8. doi: 10.1128/AAC.45.9.2604-2608.2001.
5
In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
Antimicrob Agents Chemother. 2001 Jan;45(1):312-5. doi: 10.1128/AAC.45.1.312-315.2001.
6
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
7
Mycoplasma orale infection affects K+ and Cl- currents in the HSG salivary gland cell line.
In Vitro Cell Dev Biol Anim. 1996 Jun;32(6):361-5. doi: 10.1007/BF02722962.
8
In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.
Drugs. 1995;49 Suppl 2:243-5. doi: 10.2165/00003495-199500492-00056.
9
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
10
In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.
Antimicrob Agents Chemother. 1994 Apr;38(4):790-8. doi: 10.1128/AAC.38.4.790.
本文引用的文献
1
2
Antimycoplasmal activity of ofloxacin (DL-8280).
Antimicrob Agents Chemother. 1983 Mar;23(3):509-11. doi: 10.1128/AAC.23.3.509.
3
Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro.
Am J Med Sci. 1967 Jun;253(6):639-50. doi: 10.1097/00000441-196706000-00001.
4
Comparison of antibiotics in the treatment of mycoplasmal pneumonia.
Arch Intern Med. 1970 Apr;125(4):680-4.
5
Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics.
J Pediatr. 1970 Mar;76(3):438-43. doi: 10.1016/s0022-3476(70)80485-1.
6
The effect of antibiotics on Mycoplasma pneumoniae in vitro and in vivo.
Am J Epidemiol. 1967 Jul;86(1):225-37. doi: 10.1093/oxfordjournals.aje.a120727.
7
Heat-lability and organic solvent-solubility of mycoplasma antigens.
Ann N Y Acad Sci. 1967 Jul 28;143(1):676-81. doi: 10.1111/j.1749-6632.1967.tb27713.x.
8
Susceptibility of Mycoplasma pneumoniae to antibiotics in vitro.
Jpn J Microbiol. 1974 Mar;18(2):149-55. doi: 10.1111/j.1348-0421.1974.tb00803.x.
9
Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella.
J Antimicrob Chemother. 1987 Nov;20 Suppl B:75-80. doi: 10.1093/jac/20.suppl_b.75.
10
[In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
Pathol Biol (Paris). 1988 May;36(5):496-9.
Zotero 插件